http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2298554-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_42e94091a4fc81b8d0237117707cc7ee |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D495-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40 |
| filingDate | 2001-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2007-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d27e0dbae80105f4068d78c0854fa976 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_15b2ad8f554f5a84a6276a2e4f7acfe2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_831712324d81cf17bf1dd569f2d5f844 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2111b93dd876cd13fc24f51ef4ea8634 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_46284d7cd63ad55428d6689848075320 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ca4b03f4c083b1144a40b8bac139a25 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c8967e3adf0cf961dde3c81ab5d592af http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e2674ec1381c5d1ce3690d678524abcd |
| publicationDate | 2007-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2298554-C2 |
| titleOfInvention | Condensed heterocyclic succinamide compounds |
| abstract | FIELD: organic chemistry, medicine, oncology. n SUBSTANCE: invention relates to condensed heterocyclic succinamide compounds of the formula (I): , their pharmaceutically acceptable salts, solvates or isomers wherein G represents mono- or polycyclic aryl or heterocyclic group substituted possibly at one or more positions; L represents a bond, -(CR 7 R 7' ) n (wherein n = 1; R 7 and R 7' represents independently hydrogen atom (H), alkyl or substituted alkyl) or -CH 2 -NH-; Z 1 represents oxygen atom (O); Z 2 represents O; A 1 and A 2 represent -CR 7 or in common with R 7 from group W is a heterocyclic ring wherein oxygen represents a heteroatom; Y represents -O-, -SO-, -N(V 2 )-, -CH 2 -N(V 2 )-, -CO-N-(alkyl)-, -CH 2 -S-, -CH 2 -SO 2 -; V 2 represents hydrogen atom, alkyl, arylalkyl, -CO-alkyl, -CO-O-aryl, -CO-O-arylalkyl; W represents -CR 7 R 7' -CR 7 R 7' -, -CR 7 R 7' -C=O, -NR 9 -, -CR 7 R 7' -, -N=CR 8 -, -N=N, -NR 9 -NR 9' -, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo- or substituted heterocyclo-group, aryl or substituted aryl wherein if W doesn't mean -NR 9 -CR 7 R 7' -, -N=CR 8 -, -N=N, -NR 9 -NR 9' - or heterocyclo- or substituted heterocyclo-group then Y must mean -O-, -CH 2 -S-, -SO-, -CH 2 -SO 2 -, -N-(V 2 )- or -CH 2 -N-(V 2 )-; Q 1 and Q 2 represent hydrogen atom (H). Also, invention describes a method for synthesis of intermediate compounds in synthesis of compounds of the formula (I), using the latter for preparing agents modeling function of the nuclear hormone receptors. Compounds of the formula (I) can be used in treatment of prostate cancer. n EFFECT: improved method of synthesis, valuable medicinal properties of compounds. n 8 cl, 11 tbl, 463 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2791904-C2 |
| priorityDate | 2000-09-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1535.